In summary, the results of our study showed that SGLT2 inhibitors were associated with improvements in glycaemic control and reduced risk of hospitalisations and deaths in patients with T2DM managed in the public healthcare setting in Singapore, and were well tolerated. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.